Photo of Matthew S. Davids,  MD

Matthew S. Davids, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5847
Fax: (617) 582-7890

Matthew S. Davids, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Lymphoma Group, Medical Oncology - Division of Hematologic Malignancies, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

In the laboratory of Dr. Anthony Letai at DFCI, I study resistance to treatment in chronic lymphocytic leukemia (CLL) by utilizing BH3 profiling to investigate the mechanisms underlying stroma-mediated resistance to apoptosis. I am developing an early-phase clinical trial to evaluate pharmacologic combinations that might mitigate stroma-mediated treatment resistance and thereby improve the treatment of CLL. In addition to my laboratory work, I also serve as an attending physician in the DFCI lymphoma group, and as the principal investigator of clinical trials in CLL and non-Hodgkin lymphoma.

Publications

Powered by Harvard Catalyst
  • Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma. Clin Cancer Res 2015. PubMed
  • Davids MS, Alyea EP. The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2015; 10:18-27. PubMed
  • Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells. British Journal of Haematology 2015. PubMed
  • Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka KI, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica 2014. PubMed
  • Brem EA, Davids MS. Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma 2014. PubMed
  • Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol 2014; 150:280-7. PubMed
  • Davids MS. Boldly Targeting Kinases without mutations. Blood 2014; 123:1119-21. PubMed
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. British Journal of Haematology 2013; 163:123-6. PubMed
  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma. Haematologica 2013. PubMed
  • Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma 2013. PubMed
  • Davids MS, Brown JR. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013; 27:329-39. PubMed
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. British Journal of Haematology 2013; 160:608-17. PubMed
  • Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell 2013; 23:139-41. PubMed
  • Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012; 120:3501-9. PubMed
  • Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res 2012; 72:4193-203. PubMed
  • Davids MS, Burger JA. Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol 2012. PubMed
  • Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 2011. PubMed
  • Davids MS, Case C, Hornung R, Chao NJ, Chute JP, Coleman CN, Weisdorf D, Confer DL, Weinstock DM. Assessing surge capacity for radiation victims with marrow toxicity. Biol Blood Marrow Transplant 2010; 16:1436-41. PubMed
  • Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol 2010; 85:787-90. PubMed
  • Davids MS, Steensma DP. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther 2010; 10:309-19. PubMed
  • Davids MS, Case C, Confer DL, Weisdorf DJ, Weinstock DM. Medical management of radiation victims in the United States. Health Phys 2010; 98:833-7. PubMed
  • Davids MS, Davids M, Charlton A, Ng SS, Chong ML, Laubscher K, Dar M, Hodge J, Soong R, Goh BC. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol 2009; 27:e97-100. PubMed
  • Davids MS, Crawford E, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Phelan MC, Comb MJ, Melnick MB. STK25 is a candidate gene for pseudopseudohypoparathyroidism. Genomics 2001; 77:2-4. PubMed
Hide